(July 28, 2014) Research published last week in Behavioral Medicine suggests that most high-risk women (>75%) do not know their risk for ovarian cancer. Women with a documented deleterious mutation … Continued
(July 21, 2014) According to research funded in part by OCRF, circulating tumor cells spread ovarian cancer through the bloodstream, homing in on a sheath of abdominal fatty tissue where … Continued
(July 8, 2014) Frequent mutations in the ARID1A gene have been previously discovered in ovarian endometrioid and clear-cell cancers. Now research supported by OCRF has provided direct evidence that it … Continued
Q&A with John Weroha, MD, PhD 2014 Liz Tilberis Early Career Award Mayo Clinic Were you always in interested in science? By the … Continued
(July 1, 2014) There is “little evidence” that the use of conventional fertility hormones used for ovarian stimulation in the treatment of infertility increases the long-term risk of breast and … Continued
(June 25, 2014) Research presented at the annual meeting of the American Society of Clinical Oncology earlier this month suggests that palliative care delivered at the time of cancer diagnosis … Continued
(June 24, 2014) Earlier this month, researchers reported results of a Phase II trial which looked at efficacy and safety of a biweekly gemcitabine, carboplatin, and bevacizumab combination in patients … Continued
On Monday, June 16, 2014, Dr. Douglas Levine of Memorial Sloan Kettering Cancer Center presented a free webinar focusing on research news that was presented at 2014’s medical meetings. In … Continued
Promising new combination treatments for ovarian cancer Dr. Joyce Liu, MD, on behalf of researchers from the National Cancer Institute (NCI) and Dana Farber Cancer Institute (DFCI), presented striking results … Continued
Posted by Laura Koontz on June 5, 2014 The 50th Annual Conference of the American Society of Clinical Oncology, held May 30 – June 3 in Chicago, featured a number of promising and thought … Continued
(June 4, 2014) In a study presented at the American Society of Clinical Oncology annual meeting last week, researchers found that the combination of olaparib and cediranib (Recentin) kept recurrent … Continued
The Food and Drug Administration is seeking comments by June 11, 2014 on its review for Olaparib approval. Olaparib is an oral poly ADP-ribose polymerase (PARP) inhibitor that exploits DNA … Continued
Get email updates about research news, action alerts, and ways to join the fight.
